JimmyToowong Posted July 31, 2011 Share Posted July 31, 2011 Int J Radiat Oncol Biol Phys. 2010 Jun 26. [Epub ahead of print] Lack of Benefit for the Addition of Androgen Deprivation Therapy to Dose-Escalated Radiotherapy in the Treatment of Intermediate- and High-Risk Prostate Cancer. Krauss D, Kestin L, Ye H, Brabbins D, Ghilezan M, Gustafson G, Vicini F, Martinez A. Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI. Abstract PURPOSE: Assessment of androgen deprivation therapy (ADT) benefits for prostate cancer treated with dose-escalated radiotherapy (RT). METHODS AND MATERIALS: From 1991 to 2004, 1,044 patients with intermediate- (n = 782) or high-risk (n = 262) prostate cancer were treated with dose-escalated RT at William Beaumont Hospital. Patients received external-beam RT (EBRT) alone, brachytherapy (high or low dose rate), or high dose rate brachytherapy plus pelvic EBRT. Intermediate-risk patients had Gleason score 7, prostate-specific antigen (PSA) 10.0-19.9 ng/mL, or Stage T2b-T2c. High-risk patients had Gleason score 8-10, PSA >/=20, or Stage T3. Patients were additionally divided specifically by Gleason score, presence of palpable disease, and PSA level to further define subgroups benefitting from ADT. RESULTS: Median follow-up was 5 years; 420 patients receivedADT {jm: undefined in abstract - critical detail} + dose-escalated RT, and 624 received dose-escalated RT alone. For all patients, no advantages in any clinical endpoints at 8 years were associated with ADT administration. No differences in any endpoints were associated with ADT administration based on intermediate- vs. high-risk group or RT modality when analyzed separately. Patients with palpable disease plus Gleason >/=8 demonstrated improved clinical failure rates and a trend toward improved survival with ADT. Intermediate-risk patients treated with brachytherapy alone had improved biochemical control when ADT was given. CONCLUSION: Benefits of ADT in the setting of dose-escalated RT remain poorly defined. This question must continue to be addressed in prospective study. Copyright © 2010 Elsevier Inc. All rights reserved. PMID: 20584576 Forum: Very high risk Title: Very high risk improved clinical failure with ADT to higher dose radiation This extract can be found on http://PubMed.com, and is in the public domain. On PubMed.com there will be a link to the full paper (often $30, sometimes free). Any highlighting (except the title) is not by the author, but by Jim Marshall. Jim is not a doctor. This page was found on the Advanced Prostate Cancer Community for Australian men at http://advancedprost...lia.ipbhost.com. The link is hard to remember. An easier way to find it is to go to JimJimJimJim.com and click on Prostate. That's the word Jim four times, no spaces, followed by .com. If you need other help - to perhaps find someone to talk to or a local support group: Click on the Contact Jim button at http://JimJimJimJim.com. Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.